Information Provided By: 
Fly News Breaks for December 29, 2016
NUVA
Dec 29, 2016 | 09:39 EDT
Piper Jaffray analyst Matt O'Brien views NuVasive's XLIF approval in Japan as a "net positive development" given management's expectations for approval in December. He believes the company will regain all of its XLIF share put on pause during the reclassification. The analyst continues to expect "strong" earnings and sales results "this year and in the years to come," which he thinks should continue to push NuVasive shares higher in 2017. O'Brien has an Overweight rating on the name with a $70 price target.
News For NUVA From the Last 2 Days
There are no results for your query NUVA
